MGI, a China-based company committed to building core tools and technology to lead life scienc,e and South Korea based startup NGeneBio, a company specialising in next-generation sequencing-based diagnostic have signed a Memorandum of Understanding (MoU) to expand the commercial access of NGeneBio's cancer testing products globally.

This strategic partnership will enable the integration of NGeneBio's advanced diagnostic assays with MGI's high-throughput sequencing technology to accelerate the development and application of cutting-edge sequencing products in the field of precision medicine, improving patient access to precise diagnostics and personalised treatment options.

Under the MoU, NGeneBio's NGS cancer precision diagnosis products will be applied to MGI's sequencing platform DNBSEQ-G99 to provide healthcare professionals access to a powerful and reliable tool for precision diagnosis and personalised treatment.

In addition, the two parties will also join forces in various regional clinical trials and collaborations across the Asia Pacific (APAC) region to strengthen the accessibility and commercialisation of cost-effective and state-of-the-art NGS solutions through MGI's extensive network of partners and distributors.